Isofol Medical AB (publ) (ISOFOL.ST)
SEK 2.53
(3.06%)
SEK 2.53
(3.06%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -41.68 Million SEK | 74.99% |
| 2022 | -167.46 Million SEK | 18.1% |
| 2021 | -204.46 Million SEK | -9.64% |
| 2020 | -186.49 Million SEK | -11.14% |
| 2019 | -167.8 Million SEK | -86.76% |
| 2018 | -89.84 Million SEK | -23.78% |
| 2017 | -72.58 Million SEK | -13.39% |
| 2016 | -64.01 Million SEK | -57.34% |
| 2015 | -40.68 Million SEK | 0.0% |
| 2011 | -10.53 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -12.12 Million SEK | -25.18% |
| 2024 Q1 | -9.67 Million SEK | 4.58% |
| 2023 Q4 | -10.13 Million SEK | -34.4% |
| 2023 FY | -41.87 Million SEK | 74.99% |
| 2023 Q1 | -14.39 Million SEK | 43.73% |
| 2023 Q2 | -9.54 Million SEK | 33.71% |
| 2023 Q3 | -7.54 Million SEK | 20.95% |
| 2022 Q2 | -57.15 Million SEK | -15.36% |
| 2022 FY | -167.46 Million SEK | 18.1% |
| 2022 Q1 | -49.54 Million SEK | 21.18% |
| 2022 Q4 | -25.58 Million SEK | 27.28% |
| 2022 Q3 | -35.17 Million SEK | 38.45% |
| 2021 Q4 | -62.85 Million SEK | -20.41% |
| 2021 FY | -204.46 Million SEK | -9.64% |
| 2021 Q1 | -44.73 Million SEK | 10.03% |
| 2021 Q2 | -44.66 Million SEK | 0.17% |
| 2021 Q3 | -52.2 Million SEK | -16.88% |
| 2020 Q3 | -31.5 Million SEK | 33.31% |
| 2020 Q4 | -49.72 Million SEK | -57.86% |
| 2020 FY | -186.49 Million SEK | -11.14% |
| 2020 Q1 | -58.03 Million SEK | -4.62% |
| 2020 Q2 | -47.23 Million SEK | 18.6% |
| 2019 FY | -167.8 Million SEK | -86.76% |
| 2019 Q4 | -55.47 Million SEK | -21.51% |
| 2019 Q1 | -30.37 Million SEK | -5.1% |
| 2019 Q3 | -45.65 Million SEK | -25.71% |
| 2019 Q2 | -36.31 Million SEK | -19.57% |
| 2018 Q4 | -28.89 Million SEK | -71.0% |
| 2018 FY | -89.84 Million SEK | -23.78% |
| 2018 Q2 | -20.12 Million SEK | 15.88% |
| 2018 Q1 | -23.92 Million SEK | 6.58% |
| 2018 Q3 | -16.89 Million SEK | 16.05% |
| 2017 Q3 | -19.9 Million SEK | -45.14% |
| 2017 FY | -72.58 Million SEK | -13.39% |
| 2017 Q1 | -13.19 Million SEK | 56.8% |
| 2017 Q2 | -13.71 Million SEK | -3.92% |
| 2017 Q4 | -25.61 Million SEK | -28.68% |
| 2016 Q4 | -30.54 Million SEK | -249.19% |
| 2016 Q1 | -14.73 Million SEK | -40.35% |
| 2016 FY | -64.01 Million SEK | -57.34% |
| 2016 Q2 | -10.68 Million SEK | 27.51% |
| 2016 Q3 | -8.74 Million SEK | 18.13% |
| 2015 FY | -40.68 Million SEK | 0.0% |
| 2015 Q4 | -10.5 Million SEK | 0.0% |
| 2011 FY | -10.53 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 83.259% |
| Ziccum AB (publ) | -21.56 Million SEK | -93.335% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -154.149% |
| BioArctic AB (publ) | 252.64 Million SEK | 116.499% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -4832.899% |
| Mendus AB (publ) | -100.65 Million SEK | 58.586% |
| Genovis AB (publ.) | 54.22 Million SEK | 176.872% |
| Intervacc AB (publ) | -93.57 Million SEK | 55.457% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -168.715% |
| Active Biotech AB (publ) | -46.48 Million SEK | 10.328% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 331.456% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 24.783% |
| Aptahem AB (publ) | -10.1 Million SEK | -312.509% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 87.035% |
| Kancera AB (publ) | -65.04 Million SEK | 35.914% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 69.036% |
| Fluicell AB (publ) | -26.87 Million SEK | -55.076% |
| Saniona AB (publ) | -81.06 Million SEK | 48.581% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -236.941% |
| Biovica International AB (publ) | -126.07 Million SEK | 66.937% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 1.934% |
| AcouSort AB (publ) | -17.48 Million SEK | -138.366% |
| Xintela AB (publ) | -57.23 Million SEK | 27.176% |
| Abliva AB (publ) | -96.54 Million SEK | 56.827% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 87.167% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -1089.244% |
| OncoZenge AB (publ) | -15.9 Million SEK | -162.124% |
| Amniotics AB (publ) | -29.07 Million SEK | -43.374% |
| 2cureX AB (publ) | -36.36 Million SEK | -14.63% |
| CombiGene AB (publ) | -36.3 Million SEK | -14.813% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -184.72% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 89.156% |
| Camurus AB (publ) | 532.35 Million SEK | 107.83% |
| Corline Biomedical AB | -1.78 Million SEK | -2231.264% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 76.941% |
| I-Tech AB | 24.43 Million SEK | 270.587% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 94.714% |
| Cyxone AB (publ) | -21.66 Million SEK | -92.433% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 60.663% |
| Biosergen AB | -27.26 Million SEK | -52.881% |
| Cantargia AB (publ) | -290.01 Million SEK | 85.627% |
| NextCell Pharma AB | -43.17 Million SEK | 3.449% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 76.941% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -143.813% |
| Nanologica AB (publ) | -69.96 Million SEK | 40.421% |
| SynAct Pharma AB | -224.49 Million SEK | 81.433% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 5.643% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -74.011% |
| LIDDS AB (publ) | -40.67 Million SEK | -2.481% |
| Lipum AB (publ) | -37.25 Million SEK | -11.889% |
| BioInvent International AB (publ) | -369.94 Million SEK | 88.733% |
| Alzinova AB (publ) | -16.52 Million SEK | -152.288% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 83.554% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -551.985% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 63.777% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -106.977% |
| Simris Alg AB (publ) | -36.63 Million SEK | -13.779% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 71.56% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 86.572% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 62.419% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -260.393% |